Cutting Red Tape and Double Checking to Speed up Personalized Medicine

Both biotech and pharma have long faced the burden of accelerating research in the face of massive regulation, now with more pressure to develop therapeutics and diagnostics that scale to meet the needs of the entire world under pandemic conditions.  Underlying these regulations and pressure is an inherent difficulty in accessing affordable clinical data and the general red tape involved in conducting ethical experiments.

Boston Mantra aims to help the pharma and biotech industry usher in a new era of therapeutics and companion diagnostics.  Applying expertise in the area of biotechnology product development and QAQC, Boston Mantra envisions a future of medicine that is rapidly innovating and personalized.

Image by National Cancer Institute